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NOTCH AFTER CLEAVAGE 
 
The discovery that Notch activation involves a proteolytic cleavage to release the 
intracellular domain (NICD) revolutionized the field of Notch signalling. It resulted in a simple 
model whereby the cleaved NICD enters the nucleus and activates expression of genes by 
forming a DNA bound complex with CSL.  However, is it really this simple?  The realization 
that the outcome from activating Notch varies greatly from cell to cell raised many questions 
about what governs the target gene selections in different cell types.  Insights have come 
from recent genome-wide studies, which highlight the importance of tissue-specific 
transcription factors and epigenetics.  Co-factors also have been identified that participate in 
the regulation of enhancers. Finally, it is generally assumed that once cleaved, NICD goes 
on to do its job, but with a burgeoning number of post-translations, it may not be that simple.   
 
MAIN SECTIONS: 
 
Background 
Notch is the receptor in a highly conserved cell-cell signaling pathway [1] [2].  When Notch 
engages with its ligands on neighboring cells, they render it susceptible to proteolytic 
cleavage by metalloproteases of the ADAM family (Figure 1).  Elegant structural studies 
have shown how force from ligand-receptor interactions displaces a protective shield to 
reveal the cleavage site [3].  Once the extracellular domain is cut away, the residual 
transmembrane fragment becomes a substrate for a further cleavage by the gamma-
secretase complex, containing presenilin.  This last cleavage liberates the Notch intracellular 
domain- NICD [4].  Although there may be some exceptions, most evidence points to the 
released NICD translocating rapidly into the nucleus, where it cooperates with a DNA 
binding protein CSL (CBF-1, Suppressor of Hairless, Lag-1) to regulate gene transcription 
(Figure 1).  The complex formed contains a third protein, Mastermind, (Mam; MamL1-3) in 
addition to CSL and NICD (Figure 1) [5-7]  and its primary role appears to be to activate 
transcription.   
 
While the basic principles are well established, there remain many intriguing questions about 
how Notch (NICD) performs its role and whether the mechanism is the same in all cells and 
at all genes that are regulated. It is also currently not known whether different ligands (of 
which there are 2 in Drosophila and 4 in mammals) produce NICD with different 
characteristics. Although it is hard to envisage how the type of ligand could release NICD 
with distinct properties, they may affect how much NICD is produced and how rapidly.  
Bray and Gomez-Lamarca 
Furthermore, in mammals where there are 4 Notch receptors, there is potential for the 
individual flavours of NICD to have different features.  Similarly, although the three human 
Mam proteins appear to have similar functions, they have quite diverse structures so may 
also diverge in their activities [8]. Such differences are outside the scope of this review, 
which will focus on general properties of NICD after it is released by cleavage. 
 
 
Characteristics of Notch intracellular domain  
The key role of NICD is to assemble a transcription regulatory complex, which it does in a 
stepwise manner ([5-7]).  Two regions, the N-terminal RAM domain and the ANK domain 
(Figure 1C) are involved in the interaction with its DNA binding partner, CSL.  The ANK/CSL 
interface that is generated forms a groove to accommodate the N-terminal helix of the large 
Mam co-activator. Assembly of this CSL-NICD-Mam complex is the critical step in activating 
transcription, and it is likely that Mam has a major role in the recruitment of p300/CBP 
histone actyl transferases and other factors required for transcription initiation.  A 
transactivation domain (TAD; Figure 1C) has also been defined in Notch1 and Notch2, but 
as this maps to a region with poor sequence conservation between the Notch paralogues it 
is unclear whether all NICD share this capability.  However, in mice, a deletion of Notch1 
TAD resulted in embryonic lethality and in decreased transcription of Notch target genes 
demonstrating its importance [9].  Finally the C-terminal region of NICD is a so-called PEST 
domain, (rich in prolines, glutamines serines, and threonines; Figure 1C) containing 
degrons-- motifs that promote degradation-- which are thought to confer a short half-life. 
 
NICD/CSL complexes can clearly function as individuals, binding to their well-conserved 
DNA motif (Figure 1D) at target enhancers.  However, NICD also has the capability to form 
dimers through its ANK domain [10].  This permits cooperative binding at positions where 
there are appropriately spaced head-to-head motifs, so-called SPS.  Elegant experiments in 
which binding was detected by reconstitution of a Dam methylase in the presence and 
absence of specific mutations that perturb N1ICD demonstrated that binding at certain loci, 
including Hes1 and NRARP, was indeed dimerization sensitive [11].  Likewise dimerization 
mutants in N1ICD were compromised in their ability to induce expression of a subset of 
Notch1 targets, including Myc, with consequences for both T-cell development and 
transformation [12].  While clearly enriched among responsive enhancers, it remains to be 
established what distinct effects are conferred by the head-to-head motifs, especially since 
many enhancers contain both SPS and monomeric sites [13]. 
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Tissue specific gene responses 
Genome wide studies indicate that NICD/CSL complexes occupy many sites, binding to the 
canonical motif recognized by CSL (Figure 1C). However, of the circa 12,000 optimal CSL 
binding-motifs in the Drosophila genome, only a small proportion (1%) are occupied in any 
given cell [14].  This emphasizes that other factors must influence their recruitment.  Indeed, 
the bound motifs are located in so-called active chromatin, where there are histone 
modifications associated with active or poised enhancers and where the DNA is quite 
accessible [14,15].   
 
There are a handful of genes that respond widely to NICD, which include the HES/Hey gene 
family and Myc, the latter being particularly critical in several cancers [16-18]. However, the 
outcome from activating Notch receptors differs extensively according to the cellular context 
(Figure 1B) because different cohorts of genes are regulated by NICD [19] [14,20,21].  A key 
question is what enables the different cell-type specific responses to be mounted.  How does 
NICD find the right set of genes in a given cell-type? As yet, there is a paucity of knowledge 
about this.  
 
In a few cases, tissue specific factors that cooperate with NICD to confer specificity have 
been identified. These include proteins of the Ets and Runx families.  For example, Runx 
motifs are enriched in the regions bound by NICD in T-ALL cells [11,15] and Drosophila 
hemocytes [22].  Binding of Runx and other TFs is thus likely to be a critical component to 
permit cell-type specific enhancers to respond to CSL-NICD.  However, it remains unclear 
whether there is a specific subset of TFs that have the capability to co-operate with CSL-
NICD or whether any nearby TF could do so.   
 
Although CSL-NICD bound regions in a given cell type are often enriched for the recognition 
motifs of specific transcription factors, such as Runx, these enhancers didn’t exhibit any 
stereotyped arrangement of motifs.  Instead the binding of Runx, or equivalent transcription 
factors, in the vicinity of CSL motifs appears sufficient to render an enhancer responsive [15] 
[22].  One model is that the pre-binding of TFs creates the appropriate chromatin 
environment and/or exposes CSL motifs, so that the CSL-NICD-Mam complex is able to 
access them. This model implies that the main contribution from co-operating factors may be 
to establish a permissive chromatin environment. In support, expression of a Runx factor in 
Drosophila cells was sufficient to alter the local chromatin and to enhance CSL recruitment 
[14].  In T-ALL cells, many CSL bound regions lie within a larger enhancer domain or super-
enhancer [15], arguing that there may be multiple inputs that collaborate to activate the 
enhancers.   
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These examples highlight the positive role played by cooperating TFs.  However, equally 
important is the potential of cell-type specific TFs to decommission an enhancer, so that it 
stops responding.  This is illustrated by Drosophila neural progenitors, which change their 
competence to respond to constitutively active Notch signalling due to the presence of the 
TF Eyeless/Pax6 [23].  Eyeless/Pax6 appears to directly or indirectly result in the 
decommissioning of key enhancers associated with progenitor maintenance.  Likewise, in 
the optic lobe neural lineages, Notch activity in neuronal progeny results in two different 
fates, first inducing cell death and later promoting survival.  This is dependant on a temporal 
switch in the TFs that are present [24].  Altogether these examples highlight the importance 
cell type-specific transcription factors, some acting positively to make an enhancer available 
others acting negatively to close enhancers down, so that in each cell context, a specific 
subset of CSL motifs will be rendered accessible.  In this way different Notch responses can 
be elicited, explaining the diverse outcomes from signaling.  
 
The change in enhancer accessibility is thus likely to require the recruitment of epigenetic 
regulators that locally modify the chromatin.  Indeed, many different histone modifying and 
remodelling complexes have been found to influence activity of Notch targets [25] [26]. An 
interplay between Notch activity and epigenetic regulators may also establish conditions that 
contribute to disease progression.  A persistent cell population in glioblastoma are 
dependent on Notch signalling and have up-regulated histone lysine demethylase (KDM6) 
activity, which leads to a reactivation of some developmental enhancers [27].  However, the 
consequences from altered epigenetic regulation are likely to differ depending on the 
chromatin landscape in a given cell-type, making the design of therapeutic strategies 
challenging.  
 
The concept that differential recruitment of transcription factors confers tissue/cell specific 
responses is not unique to Notch.  For example, the activation of neural specific Shh and 
BMP target genes depends on transcription factors of the SoxB family [28]. Indeed, a neural-
type response to Shh was generated when SoxB family members were expressed in the 
limb bud [29].  Possibly because HES genes are responsive in many different contexts, the 
fact that cells mount different responses to Notch has been much less emphasized than for 
other signaling pathways, where the concept of specific cellular competence has been well-
established.  However, the realization that Notch activity can be tumour promoting in some 
contexts and tumour suppressing in others (Figure 1: [30,31]), is now focusing more 
attention on the importance of understanding how different responses are programmed.  
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Revisiting the NICD “switch” 
A model, that NICD displaces co-repressors such as SMRT-HDAC from CSL to convert it 
from a repressor to an activator [32] is widely accepted and has many attractive features. It 
implies, firstly, that target loci are repressed by CSL in the absence of Notch activity.  There 
is good evidence that CSL complexed with co-repressors is important to prevent or dampen 
transcription in the absence of NICD at least at some loci (e.g. [33]. The effects are often 
quite subtle— de-repression leads to lower levels of expression that activation, emphasizing 
the important contribution from NICD beyond alleviating repression.   
 
The second characteristic of the original model, was that CSL remained resident on the DNA 
while NICD displaced the co-repressors.  How NICD achieves this has not been solved and 
recent data may be best explained by a revised model, where exchange occurs between 
different pre-formed CSL complexes.  For example, an exchange model can accommodate 
the similar measured affinity of CSL for NICD and for co-repressors [34-36] and the 
observed increase in levels of CSL bound at target loci in the presence of NICD 
[15,21,37,38]. Further studies examining the real-time dynamics of CSL interactions with 
DNA and with its partners will be needed to resolve which of these models is correct. 
 
It is also possible that there are different modes of operation depending on the target 
enhancer.  ChIP studies in mammalian cells found that some regions had enhanced CSL 
binding in the presence of NICD while others did not [15,21].  Binding of NICD itself was 
correlated with those positions where CSL binding was enhanced and was associated with 
genes that had clear-cut changes in expression.  However, in both T-ALL and C2C12 cells, 
only a fraction of CSL bound enhancers behaved in this manner [15,21].  Therefore it 
remains to be established firstly whether enhanced CSL binding is a hallmark for all Notch 
regulated genes and secondly what occurs at the other CSL bound regions.  If they are not 
Notch responsive, is CSL complexed with different co-repressors that make those positions 
“blind” to NICD or are there other factors present that mitigate any impact from changes in 
NICD?  Deciphering the characteristics of different types of enhancer we will be important for 
answering these questions.  
 
Several lines of evidence indicate that target genes are sensitive to the levels of NICD.  One 
scenario is that genes undergo linear concentration dependant responses to NICD, which 
appears the case with some isolated enhancers in transfection assays.  Results from precise 
analysis of nascent transcripts from two Notch (Glp1) regulated genes in C.elegans gonad 
also revealed a graded response. Nuclei had a probability of transcriptional firing that was 
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sensitive to the levels of NICD, a mutant with reduced levels of activity had fewer sites of 
active transcription and fewer nascent transcripts [39].  Another possibility is that target 
enhancers respond when NICD reaches a certain threshold, and then they do so in an all or 
none manner so that Notch exerts an on off switch rather than a graded response.  One 
example of a threshold effect is Bcl11b in T-cell lineages, where increasing ligand 
concentrations enhanced the frequency of Bcl11b expressing cells but not the magnitude of 
Bcl11b expression in individual cells [40].  These studies also revealed that Bcl11b activation 
required a lower Notch signal compared to other processes analyzed.  Interestingly, Bcl11b 
expression was sustained if Notch activity was removed once the gene had been activated.  
This suggests that NICD triggers BCl11b expression but is not required to maintain it, in 
contrast to many of the well-studied enhancers whose expression is lost when signaling is 
switched off.   
 
 
Modulating NICD stability 
The C-terminal PEST domain of NICD contains several motifs that are recognized by E3-
ubiquitin ligases when phosphorylated, i.e. that function as phosphodegrons.  The discovery 
that many cancer-associated mutations in Notch1 truncate the so-called PEST domain at its 
C-terminus [41] (Figure 2) has emphasized the importance of this region [42] [43].  These 
mutations lead to Notch hyperactivity due to increased stability of NICD.  Truncating 
mutations affecting Notch2 PEST have also been linked to Hajdu-Cheney syndrome (a rare 
skeletal disorder] [44]), although it has not yet been shown whether these also increase the 
stability of the ICD.   
 
Phosphodegrons in N1-ICD include Cdc4-type motifs, which are recognized by Fbw7, the 
substrate recognition subunit of an E-3 ubiquitin ligase complex [45].  Specific serine 
residues within this motif can be phosphorylated by CDK8 (Figure 2), a kinase associated 
with the Mediator complex and also with Cyclin C [46]. Its association with Mediator has led 
to the model that CDK8 recruitment to active promoters could limit N1-ICD activity by 
promoting degradation [47].  Cdc4-phosphodegron motifs are commonly phosphorylated by 
glycogen synthase kinase 3 (GSK3), which has been shown to down-regulate N2ICD [48].  
Currently we have a paucity of knowledge about the relative contributions of different 
kinases to NICD stability and about whether this differs according to the context.   
 
Other modifications such as acetylation and methylation can also influence NICD stability, 
although the effects on activity are not straightforward.  For example, different outcomes 
from acetylation/deacteylation on NICD stability have been reported.  In endothelial cells, 
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inhibitors of the deacetylase SIRT1 elicited an increase in N1-ICD levels and enhanced 
endothelial Notch responses, implying that acetylated NICD is more stable [49].  p300 
mediated acetylation of N3-ICD in T-ALL cells had the converse effect, acetylation was 
found to prime ubiquitinylation and proteasomal-mediated degradation [50].  Whether these 
differences are paralogue specific or context specific remains to be established.  Notably, 
Mam and CSL may also become acetylated and/or ubiquitinylated, which could further 
confound the outcomes [51,52].  The consequences from NICD methylation also 
demonstrate that stabilization of NICD may not always be indicative of hyperactivity. The 
arginine methylase CARM1 was found to methylate the TAD of N1-ICD at five conserved 
arginine residues (Figure 2). When methylation was prevented N1-ICD was more stable but, 
surprisingly, this led to decreased rather than increased activity [53].  Altogether it is evident 
that the outcome of signalling will be profoundly influenced by the type, level and 
combination of post-translational modifications to NICD, especially given their impact on its 
stability. 
 
Role of other co-factors 
The presence or absence of different co-factors also has the potential to modulate activity of 
NICD. Two categories of co-factors that interact with NICD-CSL complexes can be 
envisaged.  The first category encompasses factors that are required for assembling a 
functional initiation complex, to drive transcription of target genes.  These include the 
p300/CBP histone acetyl-transferases, which interact with Mam and are recruited to NICD 
bound genomic regions where they are necessary for enhancer activation.  Mediator 
complex and other components of the preinitiation complex must also be recruited, although 
whether this involves direct or indirect interactions remains to be established.  Two other 
positively acting factors, the RNA helicase Ddx5 [54,55] and the Parafibromin component of 
the CAF complex [56] are reported to stimulate NICD induced transcription. Likewise, 
interactions with Super elongation complex have also been detected in neural stem cells, 
and are proposed to augment the transcription at target loci [57].  Further investigations will 
be needed to discover how widespread the role of these different factors and whether the 
constellation of co-factors varies according to the specific gene context.  Its also important to 
consider the possibility that, besides regulating stability, post-translational modifications of 
NICD also have the potential to alter interactions with CSL and other key factors associated 
with transcriptional activity, as suggested for nemo-like kinase (NLK) in zebrafish [58] 
DYRK1A in neuroblastoma cells [59] and Casein kinase 2 (CK2) in human embryonic kidney 
cells [60] (Figure 2).  
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A second category of co-factors would include those that modulate the activity of the CSL-
NICD complex in response to specific conditions. For example, a proteomics analysis 
identified over 100 N1ICD interacting proteins that include proteins implicated in signaling 
pathway crosstalk and other protein modifiers [61].   In more directed studies, interactions of 
NICD with β-catenin and SMADs have been detected that result in a cross-talk between the 
different signaling pathways [62].  However, the consequences are not clear-cut, and it 
remains to be established how frequently these interactions occur.  In other cases, signaling 
pathways may converge onto a common co-regulator, as proposed for Parafibromin, whose 
phosphorylation state may be a mechanism that integrates the information from different 
signals [56].  Several of the other NICD interacting proteins that have emerged from specific 
interrogations contribute to repression rather than activation, including the de-methylases 
Lsd1 and Kdm5a/lid, and may be involved in mechanisms that shut down transcription 
[61,63,64]. A final point for consideration is that these interactions may be dynamic, to 
enable fine-tuning of the response. 
 
Conclusions 
The structure of the NICD-CSL-Mam complex cemented the fundamental role of NICD as a 
transcriptional activator.  The challenge in recent years has been to understand how this 
complex is deployed and regulated.  Significant insights have come from genome wide 
studies, that have demonstrated the diversity of target genes bound and have shed light on 
the epigenetic mechanisms that contribute to the cell-type specificity.  However, there are 
still many unanswered questions about what delimits the responsive enhancers in a given 
context and whether these exhibit different modes of regulation, as suggested by studies of 
Bcl11b [40].  Might some enhancers be sensitive to levels of NICD while others exhibit an 
all-or-none concentration independent response, as recently found for the Bicoid 
morphogen? [65] Indeed, we still know little about the amounts of NICD needed and the 
extent that post-translational modifications control this.  A better understanding of the latter 
is of particular relevance for diseases like some cancers in which mutations affecting NICD 
stability are implicated.  Finally, we know that the actions of NICD in the nucleus occur 
remarkably rapidly after receptor activation but the voyage of NICD from the membrane to 
the nucleus, and the extent that this is regulated, is still uncharted territory. 
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Figure Legends 
 
Figure 1: Simplified overview of Notch signaling. 
(A) Diagram illustrating Notch pathway activation and release of NICD. Ligands (green) 
on surface of signal sending cell interact with Notch receptors (purple) on 
neighbouring cells making it susceptible to cleavage by Adam 10 (light brown) and 
then γ-secretase (dark brown) to release NICD. NICD forms a complex with CSL 
(green) and Mastermind (orange) to activate target genes.   
(B) Yin-Yang of Notch illustrates that very different outcomes are programmed 
depending on which target genes are activated. 
(C) Diagram of NICD domain architecture 
(D) Logo for CSL recognition motif, height of letters indicates frequency of nucleotide at 
each position. 
 
Figure 2: Mutations and modifications in NICD 
Upper: Positions in NICD that are frequently mutated in cancers, LoF, loss of 
function; GoF, gain of function; T-All, T-cell acute lymphoblastic leukemia; CLL, 
Chronic lymphocytic leukemia; MCL, Mantle cell lymphoma; HDSCC, head and neck 
squamous cell carcinoma. 
Lower: Sites of post-translational modifications, examples where the modifications 
have been mapped. P, phosphorylation; Me, methylation; Ac, Acetylation; DYRK1A, 
Dual-specificity tyrosine phosphorylation-regulated kinase 1A;  NLK, nemo-like 
kinase; CDK8, cyclin dependant kinase 8; GSKβ, Glycogen synthase kinase 
β; CARM1, Coactivator associated arginine methyltransferase 1;   
Bray and Gomez-Lamarca 
References: 
1. Bray SJ: Notch signalling in context. Nat Rev Mol Cell Biol 2016, 17:722-735. 
2. Kovall RA, Gebelein B, Sprinzak D, Kopan R: The Canonical Notch Signaling 
Pathway: Structural and Biochemical Insights into Shape, Sugar, and Force. Dev 
Cell 2017, 41:228-241. 
**3. Gordon WR, Zimmerman B, He L, Miles LJ, Huang J, Tiyanont K, McArthur DG, Aster 
JC, Perrimon N, Loparo JJ, et al.: Mechanical Allostery: Evidence for a Force 
Requirement in the Proteolytic Activation of Notch. Dev Cell 2015, 33:729-736. 
Elegant experiments demonstrating the role of force in receptor activation , providing a 
fundamental paradigm for NICD release. 
4. Schroeter EH, Kisslinger JA, Kopan R: Notch-1 signalling requires ligand-induced 
proteolytic release of intracellular domain. Nature 1998, 393:382-386. 
5. Nam Y, Weng AP, Aster JC, Blacklow SC: Structural requirements for assembly of the 
CSL.intracellular Notch1.Mastermind-like 1 transcriptional activation complex. 
J Biol Chem 2003, 278:21232-21239. 
6. Wilson JJ, Kovall RA: Crystal structure of the CSL-Notch-Mastermind ternary 
complex bound to DNA. Cell 2006, 124:985-996. 
7. Kovall RA, Blacklow SC: Mechanistic insights into Notch receptor signaling from 
structural and biochemical studies. Curr Top Dev Biol 2010, 92:31-71. 
8. Kitagawa M: Notch signalling in the nucleus: roles of Mastermind-like (MAML) 
transcriptional coactivators. J Biochem 2016, 159:287-294. 
9. Gerhardt DM, Pajcini KV, D'Altri T, Tu L, Jain R, Xu L, Chen MJ, Rentschler S, Shestova 
O, Wertheim GB, et al.: The Notch1 transcriptional activation domain is required 
for development and reveals a novel role for Notch1 signaling in fetal 
hematopoietic stem cells. Genes Dev 2014, 28:576-593. 
10. Arnett KL, Hass M, McArthur DG, Ilagan MX, Aster JC, Kopan R, Blacklow SC: 
Structural and mechanistic insights into cooperative assembly of dimeric Notch 
transcription complexes. Nat Struct Mol Biol 2010, 17:1312-1317. 
*11. Hass MR, Liow HH, Chen X, Sharma A, Inoue YU, Inoue T, Reeb A, Martens A, 
Fulbright M, Raju S, et al.: SpDamID: Marking DNA Bound by Protein 
Complexes Identifies Notch-Dimer Responsive Enhancers. Mol Cell 2015, 59:685-
697. 
Clever split Dam-ID approach to identify co-localization of proteins at genetic loci. Results 
support the model that dimerization between NICD occurs at some enhnacers.  
12. Liu H, Chi AW, Arnett KL, Chiang MY, Xu L, Shestova O, Wang H, Li YM, Bhandoola 
A, Aster JC, et al.: Notch dimerization is required for leukemogenesis and T-cell 
development. Genes Dev 2010, 24:2395-2407. 
*13. Severson E, Arnett KL, Wang H, Zang C, Taing L, Liu H, Pear WS, Shirley Liu X, 
Blacklow SC, Aster JC: Genome-wide identification and characterization of 
Notch transcription complex-binding sequence-paired sites in leukemia cells. Sci 
Signal 2017, 10. 
Used a FRET method to determine motifs recognized by N1-ICD dimers and from the results, 
estimated that about a third of direct Notch target genes depend on paired binding 
sites. 
*14. Skalska L, Stojnic R, Li J, Fischer B, Cerda-Moya G, Sakai H, Tajbakhsh S, Russell S, 
Adryan B, Bray SJ: Chromatin signatures at Notch-regulated enhancers reveal 
large-scale changes in H3K56ac upon activation. EMBO J 2015, 34:1889-1904. 
Analysis of chromatin states at Notch regulated enhancers shows that CSL binding is related 
to accessibility of sites. Runx co-regulators can render enhancers more accessible.    
Bray and Gomez-Lamarca 
15. Wang H, Zang C, Taing L, Arnett KL, Wong YJ, Pear WS, Blacklow SC, Liu XS, Aster 
JC: NOTCH1-RBPJ complexes drive target gene expression through dynamic 
interactions with superenhancers. Proc Natl Acad Sci U S A 2014, 111:705-710. 
16. Klinakis A, Szabolcs M, Politi K, Kiaris H, Artavanis-Tsakonas S, Efstratiadis A: Myc is 
a Notch1 transcriptional target and a requisite for Notch1-induced mammary 
tumorigenesis in mice. Proc Natl Acad Sci U S A 2006, 103:9262-9267. 
17. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, Barnes KC, O'Neil J, 
Neuberg D, Weng AP, et al.: NOTCH1 directly regulates c-MYC and activates a 
feed-forward-loop transcriptional network promoting leukemic cell growth. Proc 
Natl Acad Sci U S A 2006, 103:18261-18266. 
18. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, Del Bianco 
C, Rodriguez CG, Sai H, Tobias J, et al.: c-Myc is an important direct target of 
Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006, 
20:2096-2109. 
19. Wang H, Zou J, Zhao B, Johannsen E, Ashworth T, Wong H, Pear WS, Schug J, 
Blacklow SC, Arnett KL, et al.: Genome-wide analysis reveals conserved and 
divergent features of Notch1/RBPJ binding in human and murine T-
lymphoblastic leukemia cells. Proc Natl Acad Sci U S A 2012, 108:14908-14913. 
20. Krejci A, Bernard F, Housden BE, Collins S, Bray SJ: Direct response to Notch 
activation: signaling crosstalk and incoherent logic. Sci Signal 2009, 2:ra1. 
21. Castel D, Mourikis P, Bartels SJ, Brinkman AB, Tajbakhsh S, Stunnenberg HG: 
Dynamic binding of RBPJ is determined by Notch signaling status. Genes Dev 
2013, 27:1059-1071. 
22. Terriente-Felix A, Li J, Collins S, Mulligan A, Reekie I, Bernard F, Krejci A, Bray S: 
Notch cooperates with Lozenge/Runx to lock haemocytes into a differentiation 
programme. Development 2013, 140:926-937. 
*23. Farnsworth DR, Bayraktar OA, Doe CQ: Aging Neural Progenitors Lose Competence 
to Respond to Mitogenic Notch Signaling. Curr Biol 2015, 25:3058-3068. 
Example that illustrates change in cellular competence to respond to NICD 
24. Bertet C, Li X, Erclik T, Cavey M, Wells B, Desplan C: Temporal patterning of 
neuroblasts controls Notch-mediated cell survival through regulation of Hid or 
Reaper. Cell 2014, 158:1173-1186. 
25. Schwanbeck R: The role of epigenetic mechanisms in Notch signaling during 
development. J Cell Physiol 2015, 230:969-981. 
26. Giaimo BD, Oswald F, Borggrefe T: Dynamic chromatin regulation at Notch target 
genes. Transcription 2017, 8:61-66. 
27. Liau BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, Miller TE, Venteicher 
AS, Hebert CH, Carey CD, Rodig SJ, et al.: Adaptive Chromatin Remodeling 
Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. Cell Stem Cell 
2017, 20:233-246 e237. 
28. Sagner A, Briscoe J: Morphogen interpretation: concentration, time, competence, 
and signaling dynamics. Wiley Interdiscip Rev Dev Biol 2017, 6. 
29. Oosterveen T, Kurdija S, Enstero M, Uhde CW, Bergsland M, Sandberg M, Sandberg R, 
Muhr J, Ericson J: SoxB1-driven transcriptional network underlies neural-specific 
interpretation of morphogen signals. Proc Natl Acad Sci U S A 2013, 110:7330-
7335. 
30. Koch U, Radtke F: Notch and cancer: a double-edged sword. Cell Mol Life Sci 2007, 
64:2746-2762. 
31. Aster JC, Pear WS, Blacklow SC: The Varied Roles of Notch in Cancer. Annu Rev 
Pathol 2017, 12:245-275. 
Bray and Gomez-Lamarca 
32. Kao HY, Ordentlich P, Koyano-Nakagawa N, Tang Z, Downes M, Kintner CR, Evans 
RM, Kadesch T: A histone deacetylase corepressor complex regulates the Notch 
signal transduction pathway. Genes Dev 1998, 12:2269-2277. 
33. Castro B, Barolo S, Bailey AM, Posakony JW: Lateral inhibition in proneural 
clusters: cis-regulatory logic and default repression by Suppressor of Hairless. 
Development 2005, 132:3333-3344. 
34. VanderWielen BD, Yuan Z, Friedmann DR, Kovall RA: Transcriptional repression in 
the Notch pathway: thermodynamic characterization of CSL-MINT (Msx2-
interacting nuclear target protein) complexes. J Biol Chem 2011, 286:14892-
14902. 
35. Collins KJ, Yuan Z, Kovall RA: Structure and function of the CSL-KyoT2 
corepressor complex: a negative regulator of Notch signaling. Structure 2014, 
22:70-81. 
36. Yuan Z, Praxenthaler H, Tabaja N, Torella R, Preiss A, Maier D, Kovall RA: Structure 
and Function of the Su(H)-Hairless Repressor Complex, the Major Antagonist of 
Notch Signaling in Drosophila melanogaster. PLoS Biol 2016, 14:e1002509. 
37. Krejci A, Bray S: Notch activation stimulates transient and selective binding of 
Su(H)/CSL to target enhancers. Genes Dev 2007, 21:1322-1327. 
38. Housden BE, Fu AQ, Krejci A, Bernard F, Fischer B, Tavare S, Russell S, Bray SJ: 
Transcriptional dynamics elicited by a short pulse of notch activation involves 
feed-forward regulation by E(spl)/Hes genes. PLoS Genet 2013, 9:e1003162. 
**39. Lee C, Sorensen EB, Lynch TR, Kimble J: C. elegans GLP-1/Notch activates 
transcription in a probability gradient across the germline stem cell pool. Elife 
2016, 5.  
Single molecule methods show the value of studying nascent transcripts to identify active 
transcription sites. Results reveal the pobabalistic nature of Notch-dependent 
transcription sites, on a cell level, that nevertheless exhibit a graded response in the 
tissue.  
*40. Kueh HY, Yui MA, Ng KK, Pease SS, Zhang JA, Damle SS, Freedman G, Siu S, 
Bernstein ID, Elowitz MB, et al.: Asynchronous combinatorial action of four 
regulatory factors activates Bcl11b for T cell commitment. Nat Immunol 2016, 
17:956-965. 
Analyzing the response of Bcl-11b during T-cell comitments, they investigated the  effects of 
Notch on a cell by cell basis, and tested the consequences from varying levels of 
activation to show it affected the number of cells expressing Bcl11b but not the levels 
per cell. 
41. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C, 
Blacklow SC, Look AT, Aster JC: Activating mutations of NOTCH1 in human T 
cell acute lymphoblastic leukemia. Science 2004, 306:269-271. 
42. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, Escaramis G, 
Jares P, Bea S, Gonzalez-Diaz M, et al.: Whole-genome sequencing identifies 
recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-
105. 
43. Wang K, Zhang Q, Li D, Ching K, Zhang C, Zheng X, Ozeck M, Shi S, Li X, Wang H, et 
al.: PEST domain mutations in Notch receptors comprise an oncogenic driver 
segment in triple-negative breast cancer sensitive to a gamma-secretase 
inhibitor. Clin Cancer Res 2015, 21:1487-1496. 
44. Isidor B, Lindenbaum P, Pichon O, Bezieau S, Dina C, Jacquemont S, Martin-Coignard 
D, Thauvin-Robinet C, Le Merrer M, Mandel JL, et al.: Truncating mutations in the 
Bray and Gomez-Lamarca 
last exon of NOTCH2 cause a rare skeletal disorder with osteoporosis. Nat Genet 
2011, 43:306-308. 
45. Welcker M, Clurman BE: FBW7 ubiquitin ligase: a tumour suppressor at the 
crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008, 8:83-
93. 
46. Li N, Fassl A, Chick J, Inuzuka H, Li X, Mansour MR, Liu L, Wang H, King B, Shaik S, 
et al.: Cyclin C is a haploinsufficient tumour suppressor. Nat Cell Biol 2014, 
16:1080-1091. 
47. Fryer CJ, White JB, Jones KA: Mastermind recruits CycC:CDK8 to phosphorylate 
the Notch ICD and coordinate activation with turnover. Mol Cell 2004, 16:509-
520. 
48. Espinosa L, Ingles-Esteve J, Aguilera C, Bigas A: Phosphorylation by glycogen 
synthase kinase-3 beta down-regulates Notch activity, a link for Notch and Wnt 
pathways. J Biol Chem 2003, 278:32227-32235. 
49. Guarani V, Deflorian G, Franco CA, Kruger M, Phng LK, Bentley K, Toussaint L, 
Dequiedt F, Mostoslavsky R, Schmidt MH, et al.: Acetylation-dependent regulation 
of endothelial Notch signalling by the SIRT1 deacetylase. Nature 2011, 473:234-
238. 
50. Palermo R, Checquolo S, Giovenco A, Grazioli P, Kumar V, Campese AF, Giorgi A, 
Napolitano M, Canettieri G, Ferrara G, et al.: Acetylation controls Notch3 stability 
and function in T-cell leukemia. Oncogene 2012, 31:3807-3817. 
51. Farshbaf M, Lindberg MJ, Truong A, Bevens Z, Chambers E, Pournara A, Wallberg AE, 
White JB: Mastermind-Like 1 Is Ubiquitinated: Functional Consequences for 
Notch Signaling. PLoS One 2015, 10:e0134013. 
52. Horvath M, Mihajlovic Z, Slaninova V, Perez-Gomez R, Moshkin Y, Krejci A: The 
silent information regulator 1 (Sirt1) is a positive regulator of the Notch pathway 
in Drosophila. Biochem J 2016, 473:4129-4143. 
*53. Hein K, Mittler G, Cizelsky W, Kuhl M, Ferrante F, Liefke R, Berger IM, Just S, Strang 
JE, Kestler HA, et al.: Site-specific methylation of Notch1 controls the amplitude 
and duration of the Notch1 response. Sci Signal 2015, 8:ra30. 
Example showing importance of novel post-translational modifications on NICD stability  
54. Jung C, Mittler G, Oswald F, Borggrefe T: RNA helicase Ddx5 and the noncoding 
RNA SRA act as coactivators in the Notch signaling pathway. Biochim Biophys 
Acta 2013, 1833:1180-1189. 
55. Lin S, Tian L, Shen H, Gu Y, Li JL, Chen Z, Sun X, You MJ, Wu L: DDX5 is a positive 
regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic 
leukemia. Oncogene 2013, 32:4845-4853. 
56. Kikuchi I, Takahashi-Kanemitsu A, Sakiyama N, Tang C, Tang PJ, Noda S, Nakao K, 
Kassai H, Sato T, Aiba A, et al.: Dephosphorylated parafibromin is a 
transcriptional coactivator of the Wnt/Hedgehog/Notch pathways. Nat Commun 
2016, 7:12887. 
57. Liu K, Shen D, Shen J, Gao SM, Li B, Wong C, Feng W, Song Y: The Super 
Elongation Complex Drives Neural Stem Cell Fate Commitment. Dev Cell 2017, 
40:537-551 e536. 
58. Ishitani T, Hirao T, Suzuki M, Isoda M, Ishitani S, Harigaya K, Kitagawa M, Matsumoto 
K, Itoh M: Nemo-like kinase suppresses Notch signalling by interfering with 
formation of the Notch active transcriptional complex. Nat Cell Biol 2010, 12:278-
285. 
Bray and Gomez-Lamarca 
59. Fernandez-Martinez J, Vela EM, Tora-Ponsioen M, Ocana OH, Nieto MA, Galceran J: 
Attenuation of Notch signalling by the Down-syndrome-associated kinase 
DYRK1A. J Cell Sci 2009, 122:1574-1583. 
60. Ranganathan P, Vasquez-Del Carpio R, Kaplan FM, Wang H, Gupta A, VanWye JD, 
Capobianco AJ: Hierarchical phosphorylation within the ankyrin repeat domain 
defines a phosphoregulatory loop that regulates Notch transcriptional activity. J 
Biol Chem 2011, 286:28844-28857. 
61. Yatim A, Benne C, Sobhian B, Laurent-Chabalier S, Deas O, Judde JG, Lelievre JD, 
Levy Y, Benkirane M: NOTCH1 nuclear interactome reveals key regulators of its 
transcriptional activity and oncogenic function. Mol Cell 2012, 48:445-458. 
62. Borggrefe T, Lauth M, Zwijsen A, Huylebroeck D, Oswald F, Giaimo BD: The Notch 
intracellular domain integrates signals from Wnt, Hedgehog, TGFbeta/BMP and 
hypoxia pathways. Biochim Biophys Acta 2016, 1863:303-313. 
63. Liefke R, Oswald F, Alvarado C, Ferres-Marco D, Mittler G, Rodriguez P, Dominguez 
M, Borggrefe T: Histone demethylase KDM5A is an integral part of the core 
Notch-RBP-J repressor complex. Genes Dev 2010, 24:590-601. 
64. Xu T, Park SS, Giaimo BD, Hall D, Ferrante F, Ho DM, Hori K, Anhezini L, Ertl I, 
Bartkuhn M, et al.: RBPJ/CBF1 interacts with L3MBTL3/MBT1 to promote 
repression of Notch signaling via histone demethylase KDM1A/LSD1. EMBO J 
2017. 
65. Hannon CE, Blythe SA, Wieschaus EF: Concentration dependent chromatin states 
induced by the bicoid morphogen gradient. Elife 2017, 6. 
 
Target genes
Active
ANK PESTRAM TAD
NICD
ligand
Notch Mam
CSL
Receiving cell
CSL -interaction
Cell Fates and
Dierentiation
Cell death
Proliferation 
and growth
Progenitor 
renewal
Tumour
Promoting
Tumour
Suppressing
Yin Yang of Notch 
Responses 
Adam10
γ-secretase
NICD CSL
Motif
Figure 1
Figure 2
GoF  Truncating or
nonsense mutations
T-ALL, CLL, MCL
CDK8
GSK3B
LoF Truncating or
nonsense mutations
HNSCC 
DYRK1A
CK2
PP
CARM1
Me
A B
C D
P
NLK
Ac
p300
Ac
p300
